Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche's CNS Drug Pipeline Matures: More Investment, More Promise

Executive Summary

Roche Holding AG has established itself as a leader in areas like oncology, infectious disease, liver disease and inflammatory disease. Now, the company is eyeing the central nervous system as a new frontier for its R&D, stealthily building a considerable clinical-stage pipeline in the process.

You may also be interested in...



Roche’s Kadcyla Fails To Better Herceptin In First-Line Breast Cancer

Sales estimates for Roche’s Kadcyla will be cut sharply after news the MARIANNE study didn’t show the antibody-drug conjugate performing better than Herceptin in treating first-line breast cancer. Firm’s early Alzheimer’s therapy gantenerumab also fails in Phase III.

Roche Says Kadcyla Fails To Better Herceptin In First-Line Breast Cancer

Sales estimates for Roche’s Kadcyla will be cut sharply after news the MARIANNE study didn’t show the antibody-drug conjugate performing better than Herceptin in treating first-line breast cancer.

Roche Third-Quarter Pipeline Adjustments Include Advancements, Delays

Roche adjusted regulatory expectations for its pipeline during a third-quarter earnings call Oct. 16, moving up filing plans for onartuzumab (MetMAb) in metastatic non-small cell lung cancer to 2014 and pushing back an ocrelizumab filing in multiple sclerosis to 2015, both based on trial enrollment rates.

Related Content

Topics

UsernamePublicRestriction

Register

PS053470

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel